Home  |  My Account  |  View Cart  |  Checkout
   
 
 
 
 

Effigene Pharmaceuticals, Inc. ("Effigene") is a biopharmaceutical company that focuses on improving the utilization of RNA interference (RNAi) technology and facilitating the development of small interference RNA (siRNA)-based therapeutics to treat various human diseases.

EFI-001™ is a proprietary formulation for enhancing silencing effects of siRNA or shRNA in eukaryotic cells.

 
EFI-001™ is a proprietary formulation for enhancing silencing effects of siRNA or shRNA in eukaryotic cells.


 
A small molecule enhances RNA interference and promotes microRNA processing

Effigene Pharmaceuticals receives NIH STTR Grant

Emory Team Uncovers Small Molecule that Boosts RNAi Silencing; Effigene to Sell Tech

Class of antibiotics can enhance gene-silencing tool

Read All News